GT801 is an investigational anti-CD19 in vivo CAR-T therapy based on T-cell-targeted LNP technology. The product combines ionizable cationic lipids with CLAMP technology platform, featuring a distinctive T-cell-targeting VHH antibody, site-specific conjugation, and precisely controlled ligand density.